聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 25 分钟 32 秒 前

Timothy Damadian Named President and CEO of FONAR

周一, 02/08/2016 - 19:55
MELVILLE, NY--(Healthcare Sales & Marketing Network) - FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, announced today that effective February 11, 2016, Timothy Damadian, the elder son of Dr. Raymond V. Damadian, has been named President an...
Devices, Radiology, Personnel
Fonar Corp, magnetic resonance imaging

Rubicon Genomics Announces Distribution Agreement with Beckman Coulter Life Sciences for its ThruPLEX(R) Plasma-Seq Kits

周一, 02/08/2016 - 19:49
ThruPLEX® Plasma-seq Kits Enable NGS Library Preparation from Cell-Free DNA for Liquid Biopsies for Cancer Research Learn More about ThruPLEX Plasma-seq and Other Rubicon Library Preparation Kits for Research Applications at the 2016 AGBT General Me...
Diagnostics, Distribution
Rubicon Genomics, Beckman Coulter, ThruPLEX, Plasma-seq

Global Blood Therapeutics Announces Changes to Board of Directors

周一, 02/08/2016 - 15:46
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 -- (Healthcare Sales & Marketing Network) -- Global Blood Therapeutics, Inc. (GBT) (GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with signific...
Biopharmaceuticals, Personnel
Global Blood Therapeutics, sickle cell

Supernus Prevails in Oxtellar XR(R) ANDA Litigation

周一, 02/08/2016 - 15:43
A Federal Court Finds Supernus Patents Valid and Actavis Infringing Two of Them ROCKVILLE, Md., Feb. 08, 2016 -- (Healthcare Sales & Marketing Network) -- Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company focused on developing an...
Biopharmaceuticals, Generics, Litigation
Supernus Pharmaceuticals, Actavis, Oxtellar XR, oxcarbazepine

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

周一, 02/08/2016 - 15:39
Program is the Second of the Company's In Vivo Protein Replacement Platform™ Programs to Enter Clinical Development RICHMOND, Calif., Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic ...
Biopharmaceuticals, FDA
Sangamo BioSciences, Mucopolysaccharidosis, In Vivo Protein Replacement

Astellas Names James Robinson President, Americas Operations

周一, 02/08/2016 - 13:47
NORTHBROOK, Ill., Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka today announced the promotion of James Robinson as president, Americas Operations, for Astellas US LL...
Biopharmaceuticals, Personnel
Astellas Pharma

Via Surgical Ltd., Closes $6M Investment Led by Benslie Investment Group

周一, 02/08/2016 - 13:42
AMIRIM, Israel, February 8, 2016 -- (Healthcare Sales & Marketing Network) -- Via Surgical Ltd., a leading developer of novel surgical fixation technologies for mesh placement in hernia repair, announced today the company has secured a $6M investment led ...
Devices, Surgery, Venture Capital
Via Surgical, FasTouch, Deployable Suture Fixation, hernia repair

BMC Medical Co., Ltd Wins Patent Infringement Litigation Against ResMed

周一, 02/08/2016 - 13:37
BEIJING, Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- BMC Medical Co., Ltd has won a global patent infringement litigation action against ResMed Inc. The United States Patent and Trademark Office (USPTO) issued a series of judgments in con...
Devices, Litigation
BMC Medical Co, ResMed, sleep therapy

Atlas Genetics Gains CE Approval for First Product

周一, 02/08/2016 - 13:33
Approval of Chlamydia test for marketing and sale in Europe BATH, England, February 8, 2016 -- (Healthcare Sales & Marketing Network) -- Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) mol...
Diagnostics, Regulatory
Atlas Genetics, Chlamydia, io CT test

STENTYS initiates the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication

周一, 02/08/2016 - 13:28
PRINCETON, N.J. & PARIS--(Healthcare Sales & Marketing Network)--STENTYS (FR0010949404 — STNT) (Paris:STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces the first distribution a...
Devices, Interventional, Product Launch
STENTYS, Self-Apposing Stent, drug eluting stent

CTI BioPharma Provides Update On Investigational Agent Pacritinib

周一, 02/08/2016 - 13:21
FDA Places Partial Clinical Hold on Pacritinib IND; Currently Enrolled Patients Benefiting from Pacritinib Can Continue Receiving Pacritinib Phase 3 Clinical Trial (PERSIST-2) Evaluating Pacritinib for Patients with Myelofibrosis and Platelet Counts of ...
Biopharmaceuticals, Oncology
CTI BioPharma, Pacritinib, myelofibrosis

Prism Medical Announces Appointment of Chief Executive Officer

周六, 02/06/2016 - 15:06
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Prism Medical Ltd. ("Prism Medical" or the "Company") (TSX VENTURE:PM) announced today that Ross Scavuzzo, its Senior Vice President, Canada, has been appointed as Chief Executi...
Devices, Personnel
Prism Medical, ErgoSafe

Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa

周五, 02/05/2016 - 13:35
SAN FRANCISCO, February 5, 2016 -- (Healthcare Sales & Marketing Network) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has...
Biopharmaceuticals, Ophthalmology, FDA
Amarantus Bioscience, retinitis pigmentosa

TVA Medical Receives Additional Reimbursement in Germany for the everlinQ(TM) endoAVF System

周五, 02/05/2016 - 13:27
AUSTIN, Texas, Feb. 5, 2016 -- (Healthcare Sales & Marketing Network) -- TVA Medical, Inc., a medical device company developing innovative therapies for end-stage renal disease (ESRD), today announced that its everlinQTM endoAVF System has received NUB (G...
Devices, Interventional, Reimbursement
TVA Medical, everlinQ, endoAVF System, ESRD

Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed

周五, 02/05/2016 - 13:18
Incoming CEO James Garner appointed to the Board of Novogen New Chairman and Deputy Chairman appointed Composition of Board Committees changes SYDNEY, Feb. 5, 2016 -- (Healthcare Sales & Marketing Network) -- Australian-US drug discovery and deve...
Biopharmaceuticals, Oncology, Personnel
Novogen, Cantrixil, Anisina, superbenzopyrans

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong